Autoimmunity: a risk factor for allosensitisation to blood products?
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Transfusion of blood products sensitises some patients to isoantigens. We report three cases of the formation of multiple persistent isoantibodies that occurred in association with! a complex of autoimmune diseases over 10 months.
Case histories
Case 1 -A 50 year old woman with a history of rheumatoid arthritis treated with various agents including prednisolone was admitted for odontoid peg surgery. She had had two pregnancies, and six years before admission she had received 5 units of packed erythrocytes during three orthopaedic operations. Clinically she had vitiligo and hypothyroidism. Initially only anti-rhesus E and anti-Duffy antibodies were detected. Postoperative transfusion was followed by a delayed haemolytic transfusion reaction at 10 days. Further surgery for a cerebrospinal fluid leak required repeat transfusion, which disclosed additional antiKell, anti-rhesus C, anti-Kidd, and HLA antibodies to 80% of a lymphocyte panel (North West Thames Regional Blood. Transfusion Centre, Edgware). Further episodes of haemolysis occurred until fully crossmatched blood (also anti-S negative) was used. She was managed symptomatically and made a good recovery.
Case 2-A 65 year old nullipara presented with a right frontal glioma and, a history of aplastic anaemia managed by splenectomy (eight years). She had been treated with prednisolone five years previously. Her total transfusion history was 8 units of packed cells up to six years previously and 12 units of platelets up to nine years previously. Her autoimmunity was manifested by vitiligo, hypothyroidism, and pernicious anaemia. On admission she was anaemic (105 g/l) and thrombocytopenic (26x109/l) and was crossmatched for red cell transfusion. Repeat crossmatching two hours after platelet transfusion, when she remained thrombocytopenic, disclosed HLA antibodies. This necessitated tissue typing before revision of her bone flap. During the transfusions she had a mild transfusion reaction on four occasions. Eventually she recovered.
Case 3-A 51 year old woman was admitted for thymectomy after presenting with myasthenia gravis. She had a previous history of hypothyroidism and breast adenocarcinoma and was receiving long term prednisolone. She had borne three children. Her total transfusion history was 4 units of packed cells two years previously. Her thymectomy was uneventful and she did not require transfusion. She made a good recovery.
The table gives details of the antibody profiles in the three cases.
Comment
Blood product isoantibodies and autoantibodies are becoming commoner with the frequency of multiple transfusions and bone marrow transplant operations. The prevalence of isoantibodies varies from 0-5% to 3 8%' or a reaction occurs to roughly one in 4000 units of blood transfused.2 Usually, however, antibodies are to only one blood group-for example, rhesus-and they occur in 10-36% of multitransfused patients.34 Rarely two blood groups are affected (10% of delayed transfusion reactions), but three or more are very rare (1%). Most of these antibodies decline in titre over four years to 60-80% of their original prevalence.5 AntiKidd and anti-rhesus E are commonly seen in allosensitisation and also reappear on restimulation, as occasionally does anti-Duffy. 4 Our patients were unusual in that their exposure to blood products was small and had occurred several years previously. Multitransfusion studies cite transfusions of 10-20 units one year previously.3 The three patients were immunosuppressed with steroids, which should have reduced their predisposition to allosensitisation.
All three patients were of the sex and age groups particularly affected by autoimmune diseases, and all showed pronounced immune dysfunction manifested by formation of multiple autoantibodies. We suggest that this defect in their immune suppressor mechanisms might also have predisposed them to the induction and persistence of antibodies against blood products. This type of patient might therefore benefit from more accurate crossmatching for minor blood groups to avoid the possibility of later delayed haemolytic transfusion reactions.
ADDENDUM-Since submitting this report we have seen a further case of a 59 year old nullipara with
Results of blood crossmatching and screeningfor autoantibodies and isoantibodies in three patients Case 
Our results suggest that acrivastine and terfenadine can partially relieve itching in atopic eczema. These data are perhaps more striking when it is considered that these antihistamines were effective against a background of concomitant treatment with a moderately potent corticosteroid ointment and an emollient soap substitute. This suggests that these agents can enhance the benefits of routine topical treatment for atopic eczema.
The ability of two separate agents, whose only known mechanism of action is through blockade of H1 histamine receptors and which are both devoid of any major sedative action, to alleviate itching in some patients with atopic eczema has interesting mechanistic implications. The data imply that histamine has an active role, though the mechanisms of itch may not be homogenous in nature and the part played by histamine may be greater or smaller in individual patients.
The widely held belief that treatment of itching in atopic eczema with older, traditional antihistamines operates only by the well known sedation associated with such agents must be questioned.
